Search clinical trials for: BMS-986263

Total 3156 results

Bristol-Myers Squibb

Active, not recruiting

A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting (ARTISTYK)

Psoriasis

United States, Puerto Rico
Bristol-Myers Squibb

Terminated

A Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Participants With Moderate to Severe Ulcerative Colitis

Colitis, Ulcerative

United States, Australia, Canada, Germany, Poland, Puerto Rico, United Kingdom, Netherlands
Bristol-Myers Squibb

Completed

To Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding in Lung Using PET (Positron Emission Tomography) In Healthy Volunteers

Immunology

United States
Mark Stein
Bristol-Myers Squibb

Active, not recruiting

Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)

Prostate Cancer | Adenocarcinoma of the Prostate

United States
Celgene

Not yet recruiting

Study to Evaluate Safety, Drug Levels, Food and Relative Bioavailability of BMS-986365 in Healthy Adult Male Participants

Healthy Participants

United States
Bristol-Myers Squibb

Completed

Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986256 in Healthy Male Participants

Healthy Participants

United States
US Department of Veterans Affairs

Completed

Patient-Centered Medication Adherence Intervention for Schizophrenia (AMAIS)

Schizophrenia

United States
Bristol-Myers Squibb

Terminated

An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's Disease

Crohn's Disease | Granulomatous Colitis | Crohn's Enteritis | Granulomatous Enteritis

Canada, Germany, Taiwan, United States, Spain, Australia, Poland, Russian Federation, Japan, Korea, Republic of, Romania, Italy, United Kingdom, Belgium, Brazil, China, Czechia, France, Hungary, Ireland, Israel, Mexico, Netherlands, P... and more
Bristol-Myers Squibb

Active, not recruiting

A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors

Advanced Solid Tumors

United States, France, Argentina, Australia, Belgium, Israel, Italy, Spain
National Alliance on Mental Illness New Hampshire
Janssen Medical Affairs

Terminated

Family Perspectives:Treatment of Psychiatric Illnesses With Atypical Long Acting Injectable Antipsychotic Medication

Psychotic Disorders

United States
NYU Langone Health

Recruiting

Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma

Melanoma | Unresectable Melanoma

United States
Bristol-Myers Squibb

Completed

A Study to Characterize the Drug Levels of an Oral Contraceptive With and Without BMS-986166 in Healthy Female Participants of Childbearing Potential

Healthy Participants

United States
Beth Israel Deaconess Medical Center
Bristol-Myers Squibb

Recruiting

Evaluating the Safety and Efficacy of Deucravacitinib Compared to Placebo Hidradenitis Suppurativa (HS).

Hidradenitis Suppurativa

United States
Bristol-Myers Squibb
Cardioxyl Pharmaceuticals, Inc

Completed

A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure

Heart Failure | Decompensated Heart Failure | Acute Heart Failure

United States, Germany, Jordan, Poland, Russian Federation
Bristol-Myers Squibb

Completed

An Investigational Study of BMS-986165 in Participants With Normal Liver Function and Participants With Mild to Severe Liver Damage

Healthy Volunteers | Liver Dysfunction

Czechia, Hungary, Slovakia
Bristol-Myers Squibb

Completed

A Study to Evaluate the Effect of Omeprazole on the Pharmacokinetics of BMS-986205 in Healthy Participants

Healthy

United States
Bristol-Myers Squibb

Completed

Effect of BMS-986165 on the Blood Levels of Metformin

Healthy Participants

United States
Jason J. Luke, MD
Bristol-Myers Squibb

Suspended

Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors

Melanoma | Carcinoma, Renal Cell | Unresectable Solid Tumors

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb; National Cancer Institute (NCI)

Recruiting

Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas

Pancreatic Cancer

United States
Bristol-Myers Squibb

Terminated

First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors

Advanced Cancer

Chile, United States, Argentina, Australia, Belgium, Canada, Finland, France, Germany, Israel, Italy, Netherlands, Norway, Poland, Romania, Spain, Switzerland
Celgene

Recruiting

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

Lymphoma, Non-Hodgkin

United States, Korea, Republic of, China, Canada, France, Spain, Denmark, Brazil, Italy, Argentina, Chile, Israel, United Kingdom, Belgium, Austria
Compugen Ltd
Bristol-Myers Squibb

Active, not recruiting

COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.

Head and Neck Cancer | Ovarian Cancer | Solid Tumor | Endometrial Neoplasms

United States
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb

Active, not recruiting

Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment

Endometrial Adenocarcinoma | Endometrial Carcinosarcoma

United States
China National Center for Cardiovascular Diseases
Peking University People's Hospital; Beijing Chao Yang Hospital; Hebei Medical...

Unknown

A New Classification and Interventional Therapy for Coronary Artery Ectasia (NCIPCAE)

Coronary Artery Ectasia

China
Bristol-Myers Squibb

Terminated

A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors

Cancer | Neoplasm | Tumors | Malignancy

United States, Canada, Spain, Switzerland
Bristol-Myers Squibb

Recruiting

A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors

Advanced Solid Tumors

Canada, United States, Argentina, France, Spain, Italy, Australia, Mexico, Chile
Bristol-Myers Squibb

Withdrawn

An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck

Head and Neck Cancer

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety, Tolerability, Kinetics, Biodistribution and Repeatability of 11C-BMS-986196 After Intravenous (IV) Administration in Healthy Participants and After Repeat IV Administration in Participants With Multiple Sclerosis

Multiple Sclerosis (MS)

United States, United Kingdom
Bristol-Myers Squibb

Active, not recruiting

A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer (RELATIVITY-123)

Colorectal Neoplasms

Italy, Canada, Korea, Republic of, Sweden, United States, Argentina, Australia, Austria, Belgium, Chile, China, Czechia, France, Germany, Japan, Netherlands, Poland, Puerto Rico, Singapore, Spain, Switzerland, Taiwan
Bristol-Myers Squibb

Withdrawn

An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Stomach Cancer | Gastric Cancer | Cancer of the Stomach | Gastroesophageal Junction

Brazil, Italy, United States, Argentina, Chile, Germany, Spain, Australia, Canada, Portugal, Mexico, Romania, Colombia, Puerto Rico
Bristol-Myers Squibb

Completed

An Investigational Study of Continuous 8-Hour Intravenous Administrations of BMS-986231 in Participants With Heart Failure and Reduced Heart Function Given a Standard Dose of Loop Diuretic

Congestive Heart Failure | Heart Decompensation | Cardiac Failure | Myocardial Failure

United Kingdom
Dana-Farber Cancer Institute
Bristol-Myers Squibb

Withdrawn

A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma

Melanoma Stage IV | Melanoma Stage III

United States
Bristol-Myers Squibb

Terminated

Phase I Ascending Multiple-Dose Study of BMS-986115 in Subjects With Advanced Solid Tumors

Various Advanced Cancer

Australia, United States, Canada
Bristol-Myers Squibb

Completed

A Single and Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Target Engagement of BMS-986147 in Healthy Subjects

Healthy

United States
Bristol-Myers Squibb

Completed

Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease

Alzheimer's Disease

France, Sweden, United States, Germany, Canada
Bristol-Myers Squibb

Completed

Japanese Phase 1 Multiple Ascending Dose (MAD) Study

Depression

Japan
Bristol-Myers Squibb

Completed

A Study Investigating the Safety, Tolerability, Drug Levels and Drug Effect of BMS-986278 in Healthy Adult Participants (Part 1) and Japanese Participants (Part 2)

Healthy Participants

United States
Bristol-Myers Squibb

Completed

A Study to Determine the Effect of Famotidine on the Drug Levels of BMS-986256 in Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Completed

Effects of BMS-986256 at Steady State on the Single Dose Pharmacokinetics of Mycophenolate Mofetil

Healthy Participants

United States
Washington University School of Medicine
Bristol-Myers Squibb

Active, not recruiting

Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer

Triple Negative Breast Cancer

United States
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Drug Levels, Physical and Chemical Changes, and Removal of BMS-986196 in Healthy Male Participants

Healthy Male Volunteers

United States
Dana-Farber Cancer Institute
Stand Up To Cancer

Active, not recruiting

Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer

Lymphoma | Solid Tumor, Childhood | Brain Tumor, Pediatric

United States, Canada
Bristol-Myers Squibb

Completed

A Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]BMS-986419 in Healthy Male Participants

Healthy Volunteers

United States
Bristol-Myers Squibb

Completed

Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986331 in Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Terminated

Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome

Sjögren's Syndrome

Australia, United States, Italy, Mexico, Colombia, Peru, Puerto Rico, South Africa, Chile, Poland, Russian Federation
Bristol-Myers Squibb

Completed

A Study to Investigate the Effects of Gastric Acid Suppression by Rabeprazole and BMS-986165 on How Fast and Complete The Drug is Absorbed Into the Body of Healthy Participants

Healthy

Netherlands
Bristol-Myers Squibb

Terminated

A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation

Paroxysmal Atrial Fibrillation

United States, Canada
Hoffmann-La Roche

Completed

Placebo-Controlled, Single and Multiple Ascending Subcutaneous Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986089 in Healthy Adult Subjects

Healthy Adults

United States
Bristol-Myers Squibb

Terminated

Safety and Efficacy Study of BMS-823778 to Treat Uncontrolled High Blood Pressure in Overweight and Obese Patients

Hypertension

Sweden, United States, Puerto Rico, Hungary, Colombia
Bristol-Myers Squibb

Terminated

Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression

Depression

France, South Africa, Sweden, United States, Australia, Italy, Argentina, Austria, Spain, Finland, India, Puerto Rico

3

Subscribe